Astera Labs, Inc. Just Beat EPS By 342%: Here's What Analysts Think Will Happen Next

Astera Labs, Inc. (NASDAQ:ALAB) investors will be delighted, with the company turning in some strong numbers with its latest results. The company beat forecasts, with revenue of US$159m, some 5.2% above estimates, and statutory earnings per share (EPS) coming in at US$0.18, 342% ahead of expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from Astera Labs' 14 analysts is for revenues of US$699.1m in 2025. This would reflect a major 43% increase on its revenue over the past 12 months. Per-share earnings are expected to jump 96% to US$0.49. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$675.1m and earnings per share (EPS) of US$0.29 in 2025. So it seems there's been a definite increase in optimism about Astera Labs' future following the latest results, with a considerable lift to the earnings per share forecasts in particular.

See our latest analysis for Astera Labs

As a result, it might be a surprise to see thatthe analysts have cut their price target 6.0% to US$104, which could suggest the forecast improvement in performance is not expected to last. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Astera Labs at US$140 per share, while the most bearish prices it at US$75.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Astera Labs' revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 60% growth on an annualised basis. This is compared to a historical growth rate of 200% over the past year. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 16% annually. So it's pretty clear that, while Astera Labs' revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Astera Labs following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Astera Labs going out to 2027, and you can see them free on our platform here..

Before you take the next step you should know about the 2 warning signs for Astera Labs that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.